Tackling the Tuberculosis Burden in Children: A Global Perspective

By Crystal Lubbe

March 12, 2025

Did you know the global burden of tuberculosis (TB) among children has dropped significantly over the past three decades? A recently published article analyses the global tuberculosis burden children face. It details the situation from 1990 to 2021 using data from the Global Burden of Disease Study 2021. The report shows a significant decrease in TB incidence, mortality, and disability-adjusted life years (DALYs) over this period. However, regional and socioeconomic disparities remain notable. Despite progress, tuberculosis continues to pose a major public health threat, especially in areas with a low socio-demographic index (SDI).

Key Insights

  • Decline in TB Burden: The global TB incidence among children and adolescents decreased by 37.4% from 1990 to 2021. Deaths also dropped by 71.7%.
  • Regional Disparities: Regions with low SDI, such as parts of Africa, still face a high tuberculosis burden in children disproportionately. High-income regions, however, have seen substantial reductions.
  • Sex Differences: Females under 20 have higher age-standardised incidence rates (ASIR), mortality rates (ASMR), and DALY rates compared to males.
  • Drug Resistance: Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) among children and adolescents are growing concerns.

Background Context

The World Health Organization (WHO) is working to end TB through its End TB Strategy. This strategy aims to reduce TB incidence and mortality by defined targets. Progress has been slow, especially in children and adolescents, where TB remains a major cause of morbidity and mortality. The COVID-19 pandemic has further complicated TB control efforts. It disrupted healthcare services and led to underreporting of TB cases. For detailed analysis, see here.

Implications

The findings have important implications for health economics and outcomes research:

  • Healthcare Infrastructure: Investing in healthcare infrastructure, especially in low SDI regions, is crucial for improving TB diagnosis and treatment.
  • Socioeconomic Interventions: Addressing factors like poverty and malnutrition can help reduce TB transmission.
  • Drug Resistance Management: Effective strategies are needed to manage drug-resistant TB and prevent its spread among vulnerable populations.
  • Research and Development: More research into pediatric TB diagnostic tools and treatment formulations is urgently needed to improve outcomes for children and adolescents.
Reference url

Recent Posts

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

Cecolin 9 HPV vaccine
        

Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China

🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?

The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.

Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.